发明名称 GUANYLATE CYCLASE RECEPTOR AGONIST FOR TREATMENT OF TISSUE INFLAMMATION AND CARCINOGENESIS
摘要 <P>PROBLEM TO BE SOLVED: To provide a method of treatment of inflammatory, pre-cancerous or cancerous tissue or polyp in a mammalian subject. <P>SOLUTION: The treatment involves administration of a composition of at least one peptide agonist of a guanylate cyclase receptor and/or other small molecules that enhance intracellular production of cGMP. The at least one peptide agonist of a guanylate cyclase receptor may be administered either alone or in combination with an inhibitor of cGMP-dependent phosphodiesterase. The inhibitor may be a small molecule, peptide, protein or other compound that inhibits the degradation of cGMP. Without requiring a particular mechanism of action, this treatment may restore a healthy balance between proliferation and apoptosis in the subject's population of epithelial cells, and also suppress carcinogenesis. Thus, the method may be used to treat, inter alia, inflammation, including gastrointestinal inflammatory disorders, general organ inflammation and asthma, and carcinogenesis of the lung, gastrointestinal tract, bladder, testis, prostate and pancreas, or polyps. <P>COPYRIGHT: (C)2009,JPO&INPIT
申请公布号 JP2009001582(A) 申请公布日期 2009.01.08
申请号 JP20080184375 申请日期 2008.07.16
申请人 SYNERGY PHARMACEUTICALS INC 发明人 SHAILUBHAI KUNWAR;NIKIFOROVICH GREGORY;JACOB GARY S
分类号 A61K9/08;C07K4/12;A61K9/14;A61K9/20;A61K9/48;A61K9/72;A61K35/74;A61K38/00;A61K38/10;A61K38/12;A61K45/00;A61K45/06;A61K47/48;A61P1/00;A61P1/04;A61P1/16;A61P1/18;A61P11/00;A61P11/06;A61P13/08;A61P13/10;A61P13/12;A61P15/00;A61P29/00;A61P35/00;A61P35/02;A61P35/04;A61P43/00;C07K7/00;C07K7/08;C07K7/64 主分类号 A61K9/08
代理机构 代理人
主权项
地址